65141-27-7

Basic information

• Product Name: Carbamic acid, (3,4-dimethoxyphenyl)-, phenyl ester
• CAS NO: 65141-27-7
• Molecular Formula: C15H15NO4
• Molecular Weight: 273.288
• Mol File: 65141-27-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Carbamic acid, (3,4-dimethoxyphenyl)-, phenyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (3,4-dimethoxyphenyl)-, phenyl ester(65141-27-7)
• EPA Substance Registry System: Carbamic acid, (3,4-dimethoxyphenyl)-, phenyl ester(65141-27-7)

Safety Data

• Hazardous Substances Data: 65141-27-7(Hazardous Substances Data)

Upstream product

• 1885-14-9 phenyl chloroformate 
• 6315-89-5 3,4-dimethoxyaniline 
• 37527-66-5 3,4-dimethoxyphenylisocyanate 
• 108-95-2 phenol 

Downstream Products

• 415692-67-0 N-(3,4-dimethoxy-phenyl)-4-methyl-benzamide 
• 1610766-80-7 (2R)-1-cyanobutan-2-yl-[(1S)-1-(3-{[(3,4-dimethoxyphenyl)carbamoyl]amino}phenyl)ethyl] carbamate 
• 788795-18-6 4-(3,4-methoxyphenyl)semicarbazide 

Relevant articles and documents

N-(3,5-dimethyladamantane-1-yl)-N'-substituted phenylurea compound as well as preparation method and application thereof

The invention belongs to the technical field of medicinal chemistry, in particular to N-(3,5-dimethyladamantane-1-yl)-N'-substituted phenylurea compounds as well as preparation methods and application thereof. The compounds have the structure shown in the formula I. The compounds are proved that the compounds can improve the image recognition memory, the working and learning memory, the spatial learning and memory ability of model rats and has good anti-alzheimer effects by the new object discrimination experiments, Y-maze experiments, positioning navigation and space exploration experiments in mats. The formula I is shown in the description.

Synthesis and biological evaluation of 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazone scaffolds as selective c-Met inhibitors

Novel quinoline derivatives bearing acyclic semicarbazones were prepared and their chemical structures as well as the relative stereochemistry were confirmed. All the synthesized compounds were evaluated for their c-Met kinase inhibitory activity and their cytotoxicity against the cell lines HT-29, MKN-45, and MDA-MB-231 in vitro. Several potent compounds were further evaluated against A549 cells. Most compounds displayed moderate to excellent activity, and the structure-activity relationship studies identified the most promising compound 35 as a selective c-Met kinase inhibitor (IC50 = 4.3 nM). Compound 35 showed a 3.5- and 18.8-fold increase in cytotoxicity in vitro against HT-29 and A549 cells, respectively, compared to that of foretinib. Poor off-target effects of compound 35 were further confirmed by the antiproliferative activity against the c-Met inhibition less sensitive MDA-MB-231 cell line (IC50 = 0.77 μM). Copyright